Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

John Rochel

Physician Assistant Fayetteville, NC Physician Assistant

NPI 1558017814 CMS profile 11368380

2041 Valleygate Dr, Fayetteville, NC 28304

Open in the dashboard

General payments

$5,470

242 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Rochel of Fayetteville, NC is reported in the CMS Open Payments database as having received $5,470 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,761 83
2024 General $1,909 91
2023 General $1,261 51
2022 General $538 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Rochel
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to John Rochel were reported at $1,761. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year John Rochel Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $538 $155 $48–$522 $149
2023 $1,261 $167 $52–$557 $160
2024 $1,909 $178 $55–$600 $164
2025 $1,761 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,181 49 payments
  2. Janssen Biotech, Inc. $628 16 payments
  3. Ardelyx, Inc. $572 26 payments
  4. Aimmune Therapeutics, Inc. $369 16 payments
  5. Phathom Pharmaceuticals, Inc. $300 25 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $299 11 payments
  7. Ironwood Pharmaceuticals, Inc $267 7 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $243 20 payments
  9. Merck Sharp & Dohme Corporation $220 11 payments
  10. Lilly USA, LLC $203 10 payments
  11. Other $1,188 51 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,319 240 payments
  2. Education $151 2 payments
Products named General payments · program years 2022–2025
  1. IBSRELA $572 26 payments
  2. TREMFYA $517 12 payments
  3. SKYRIZI $500 14 payments
  4. ZENPEP $423 21 payments
  5. RINVOQ $405 18 payments
  6. STELARA $311 6 payments
  7. Linzess $267 7 payments
  8. ENTYVIO $240 8 payments
  9. VOQUEZNA $229 12 payments
  10. DIFICID $220 11 payments
  11. Other $2,200 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

759

Median for Physician Assistant: 241

Drug cost

$321,029

Median for Physician Assistant: $4,110

Branded share of claims

36.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 29 $141,113
Linzess Linaclotide Brand 64 $85,778
Creon Lipase/Protease/Amylase Brand 20 $61,396
Trulance Plecanatide Brand 15 $13,590
Mesalamine Generic 11 $2,783
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 32 $2,410
Pantoprazole Sodium Generic 147 $2,031
Dexlansoprazole Dr Dexlansoprazole Brand 12 $1,923
Omeprazole Generic 117 $1,784
Dicyclomine Hcl Generic 79 $1,756

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBSRELA
  • Ardelyx, Inc. $215
$215 — —
STELARA
  • Janssen Biotech, Inc. $211
$211 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $192
$192 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $139
  • AbbVie, Inc. $9
$148 64 —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $148
$148 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record